May 26th 2015EP. 1: Determining the Place of PD-1s in Therapy
May 26th 2015EP. 2: Cost Issues Related to PD-1 Treatment
May 26th 2015EP. 3: Precision Medicine, the Oncology Care Model, and PD-1s
May 26th 2015EP. 4: Critical Influences for PD-1 Treatments
May 26th 2015EP. 5: Rationale for Immuno-Oncology
May 26th 2015EP. 6: Considerations Related to the Coverage of Immuno-Oncology Therapies
May 26th 2015EP. 7: NRAS Mutations in Melanoma
May 26th 2015EP. 8: Sequencing of Immunotherapy in Melanoma
May 26th 2015EP. 9: Determining Appropriate Duration of Treatment
May 26th 2015EP. 10: Considerations When Switching Therapy
May 26th 2015EP. 11: Anti-PD-1 Treatment Selection
May 26th 2015EP. 12: Anti-PD-1 Agents as Frontline Therapy
May 26th 2015EP. 13: The Rationale for Initiating Therapy with an Immuno-Oncology Drug
May 26th 2015EP. 14: Targeted Therapies and the Sequencing of Immuno-Oncology Drugs
May 26th 2015EP. 15: Integrating Immunotherapy in Lung Cancer
May 26th 2015EP. 16: Measuring Response With Immuno-Oncology Agents in NSCLC
May 26th 2015EP. 17: The Cost of Care in Immuno-Oncology
May 26th 2015EP. 18: Appropriate, Value-Based Care in Immuno-Oncology
